H.C. Wainwright Raises Purple Biotech (PPBT) Price Target, Reiterates Buy Rating
On May 30, Emily Bodnar, an analyst at H.C. Wainwright, raised her price target for Purple Biotech Ltd. (NASDAQ:PPBT) from $33 to $34 while keeping her Buy rating on the PPBT stock.
